CD44-targeted nanocarrier for cancer therapy
Cluster of differentiation 44 (CD44) is a cell surface glycoprotein overexpressed in varieties
of solid tumors including pancreatic, breast, ovary, brain, and lung cancers. It is a multi …
of solid tumors including pancreatic, breast, ovary, brain, and lung cancers. It is a multi …
Triple-negative breast cancer: a brief review about epidemiology, risk factors, signaling pathways, treatment and role of artificial intelligence
NM Almansour - Frontiers in Molecular Biosciences, 2022 - frontiersin.org
Triple-negative breast cancer (TNBC) is a kind of breast cancer that lacks estrogen,
progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for …
progesterone, and human epidermal growth factor receptor 2. This cancer is responsible for …
[HTML][HTML] Aptamer grafted nanoparticle as targeted therapeutic tool for the treatment of breast cancer
Breast carcinomas repeat their number and grow exponentially making it extremely frequent
malignancy among women. Approximately, 70–80% of early diagnosed or non-metastatic …
malignancy among women. Approximately, 70–80% of early diagnosed or non-metastatic …
Dostarlimab as a miracle drug: rising hope against cancer treatment
Immunotherapy is one of the four pillars of cancer treatment that has recently emerged as a
beacon of hope for cancer patients. Certain immunotherapies, for example, immune …
beacon of hope for cancer patients. Certain immunotherapies, for example, immune …
Genome-wide identification and analysis of prognostic features in human cancers
JC Smith, JM Sheltzer - Cell reports, 2022 - cell.com
Clinical decisions in cancer rely on precisely assessing patient risk. To improve our ability to
identify the most aggressive malignancies, we constructed genome-wide survival models …
identify the most aggressive malignancies, we constructed genome-wide survival models …
Combination therapy with nivolumab (anti-PD-1 monoclonal antibody): A new era in tumor immunotherapy
BA Kiasari, A Abbasi, NG Darestani, N Adabi… - International …, 2022 - Elsevier
Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1 or CD279)
have noticeably improved the treatment landscape of advanced cancer patients. Nivolumab …
have noticeably improved the treatment landscape of advanced cancer patients. Nivolumab …
Advancements in polymeric nanocarriers to mediate targeted therapy against triple-negative breast cancer
Triple-negative breast cancer (TNBC) is a destructive disease with a poor prognosis, low
survival rate and high rate of metastasis. It comprises 15% of total breast cancers and is …
survival rate and high rate of metastasis. It comprises 15% of total breast cancers and is …
New achievements for the treatment of triple-negative breast cancer
A Catalano, D Iacopetta, J Ceramella, A Mariconda… - Applied Sciences, 2022 - mdpi.com
Triple-negative breast cancer (TNBC) constitutes a heterogeneous group of malignancies
that are often aggressive and associated with a poor prognosis. The development of new …
that are often aggressive and associated with a poor prognosis. The development of new …
Triple-negative breast cancer brain metastasis: An update on druggable targets, current clinical trials, and future treatment options
Highlights•Treatment of brain metastasis is very challenging, due to the role of blood–brain
barrier.•Triple-negative breast cancer (TNBC) lacks targeted therapy and is challenging to …
barrier.•Triple-negative breast cancer (TNBC) lacks targeted therapy and is challenging to …
Amaryllidaceae-Type Alkaloids from Pancratium maritimum: Apoptosis-Inducing Effect and Cell Cycle Arrest on Triple-Negative Breast Cancer Cells
SAR Sancha, AV Gomes, JB Loureiro, L Saraiva… - Molecules, 2022 - mdpi.com
Aiming to find Amaryllidaceae alkaloids against breast cancer, including the highly
aggressive triple-negative breast cancer, the phytochemical study of Pancratium maritimum …
aggressive triple-negative breast cancer, the phytochemical study of Pancratium maritimum …